Filter Releases
 
Press Releases
Date Title and Summary View
Jun 4, 2017
-Elacestrant single agent Objective Response Rate (ORR) was 23% in heavily pre-treated patients with advanced ER+ breast cancer at the cut off date of April 28, 2017-  -In the 400 mg patient group with mature data, median PFS was 4.5 months and Clinical Benefit Rate at 24 weeks was 42%-...
May 24, 2017
ACTIVExtend trial demonstrated sustained statistically significant fracture risk reduction through the 3.5 years of sequential therapy: TYMLOS followed by an antiresorptive  Safety similar among all treatment groups with no cases of ONJ or AFF across the entire TYMLOS developmen...
May 15, 2017
WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced that on May 15, 2017, the Com...
May 15, 2017
WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that Jose (Pepe) Car...
May 1, 2017
US FDA approves TYMLOS™ (abaloparatide) on April 28, 2017, first new bone builder in nearly 15 years US Launch set for May 2017 24-month ACTIVExtend trial has concluded, Radius to report top-line results in 2Q 2017 WALTHAM, Mas...
Apr 28, 2017
TYMLOS is the first new anabolic (bone building) agent for postmenopausal women with osteoporosis in the United States in nearly 15 years US Commercial Launch in May Approval Based on Results at 18 months from the Landmark ACTIVE Trial and the first six mo...
Apr 5, 2017
WALTHAM, Mass., April 05, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases today announced that it will report First Quarter 2017 financial results on May 3, 2017, and that it will ...
Apr 3, 2017
The data was presented in an Oral Late-Breaker at Annual Endocrine Society Meeting "ENDO 2017" on April 1 Additional analysis of BMD gains at the wrist and fracture reductions at the ultradistal radius compared to placebo and teriparatide were presented on April 2 ...
Mar 31, 2017
Preclinical models of elacestrant activity in preclinical models of endocrine treatment resistancePreclinical studies of RAD140 activity and mechanism of action in breast cancer models WALTHAM, Mass., March 31, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical com...
Mar 10, 2017
WALTHAM, Mass., March 10, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that the U.S. Food and Drug Administra...
Feb 28, 2017
WALTHAM, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the Cowen and ...
Feb 23, 2017
US FDA PDUFA for abaloparatide-SC is March 30, 2017 Build out of Commercial Organization to be completed in 1Q 2017 24-month ACTIVExtend trial has concluded, Radius to report top-line results in 2Q 2017 WALTHAM, Mass., Feb. ...
Feb 1, 2017
— Results from interim analysis of the ACTIVExtend study of postmenopausal women with osteoporosis treated for 18 months with investigational drug abaloparatide-SC in the ACTIVE trial who were transitioned to alendronate in ACTIVExtend show statistically significant reductions at six months in the incidence of new vert...
Jan 31, 2017
WALTHAM, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its fourth quarter and full year 2016 financial results on Thursday, February 23, 2017.In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 4:30 p.m. ET on Thurs...
Jan 6, 2017
WALTHAM, Mass., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the 35th Annua...
Page:
...
Next Last
 
= add release to Briefcase